Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.

Abstract

Aim: We describe the real-world utilization and outcomes associated with managing oral factor Xa inhibitor (FXai)-related major bleeds. Materials & methods: Electronic records from 45 US hospitals were queried (ICD-10-CM billing codes D68.32, T45.515x or T45.525x) to identify major bleed hospitalizations related to FXai use. Patient demographics, bleed type (intracranial hemorrhage, gastrointestinal, critical compartment, traumatic, other), FXai taken, reversal or replacement agents administered (including andexanet alfa, four-factor prothrombin complex concentrate, fresh frozen plasma, others), in-hospital mortality and length of stay were recorded. Results: Of 3030 FXai-related hospitalizations for major bleeds, patients averaged 68years old and 47% were women. In-hospital mortality was highest for intracranial hemorrhage (23%, n=507) and lowest for gastrointestinal bleeds (4%, n=1453). In-hospital mortality was lowest (4%) for bleeds managed with andexanet alfa (n=342), compared with 10% for four-factor prothrombin complex concentrate (n=733), 11% for fresh frozen plasma (n=925) and 8% for both other agents (n=794) and no agents (n=438). Median length of stay was 5days across all agents, while ICU length of stay was shorter andexanet alfa (2days) compared with other agents (3days). Conclusion: In-hospital mortality differed by bleed type and agents administered. Andexanet alfa was associated with the lowest rate of in-hospital mortality across all bleed types.